Relationship between urinary sodium excretion and pioglitazone‐induced edema
Open Access
- 6 July 2010
- journal article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 1 (5), 208-211
- https://doi.org/10.1111/j.2040-1124.2010.00046.x
Abstract
To investigate the factors contributing to pioglitazone-induced edema, we analyzed sodium excretion and several clinical parameters before and after administration of pioglitazone. We analyzed these parameters before and after 8 weeks of administration of pioglitazone to female subjects with type 2 diabetes. When we evaluated whether a significant correlation was found between salt excretion and blood pressure, six patients showed such correlation and 20 patients did not. After 8 weeks of pioglitazone administration, five patients had developed edema, and, surprisingly, such correlation was not found in all five subjects. Salt excretion after administration of pioglitazone was significantly lower in subjects who developed edema and those who showed the correlation, and the hematocrit was significantly lower after administration in the subjects who showed the correlation, but not in the edema group. Pioglitazone-induced edema would be caused not only by fluid retention, but also by other factors, such as vascular permeability. (J Diabetes Invest, doi: 10.1111/ j.2040-1124.2010.00046.x, 2010)Keywords
This publication has 10 references indexed in Scilit:
- The role of protein kinase C activation and the vascular complications of diabetesPharmacological Research, 2007
- Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in JapanDiabetes Research and Clinical Practice, 2007
- Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedioneDiabetologia, 2006
- Self-monitoring of home blood pressure with estimation of daily salt intake using a new electrical deviceJournal of Human Hypertension, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorptionNature Medicine, 2005
- ThiazolidinedionesThe New England Journal of Medicine, 2004
- Considerations for management of fluid dynamic issues associated with thiazolidinedionesThe American Journal of Medicine, 2003
- Nonhypoglycemic Effects of ThiazolidinedionesAnnals of Internal Medicine, 2001
- Vascular Endothelial Growth Factor/Vascular Permeability Factor Enhances Vascular Permeability Via Nitric Oxide and ProstacyclinCirculation, 1998